Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
Location status: Recruiting
Location contact
Min Liang, MD
CONTACT
Yaya Yang
CONTACT
NCT Number: NCT05353660
Chronic kidney disease (CKD) has become a global public health priority over the past few decades, affecting 10-12% of the adult population and has received increasing attention. Sarcopenia describes a generalizes degenerative skeletal muscle disorder involving the loss of muscle mass, muscle function and/or physical performance. Indeed, Sarcopenia is a condition with many causes and it can be considered "primary sarcopenia" when no other cause is evident but ageing. While in the clinical practice, it also occurs in patients with chronic diseases, such as chronic kidney disease, which can be considered "secondary sarcopenia". Notably, the occurrence of sarcopenia in CKD patients is not only related with ageing, the accumulation of uremic toxins, inflammation, insulin resistance, malnutrition and oxidative stress also contribute to the muscle depletion. Moreover, sarcopenia increased risk of falls and fractures, impaired ability to perform activities of daily living, disabilities, loss of independence and increased risk of death. Hence, it is of great significance to prevent the occurrence and development of sarcopenia in patients with CKD. The purposes of this project were to investigate the prevalence of sarcopenia, further explore the risk factors for sarcopenia and detect the relationship between sarcopenia and outcomes in CKD patients.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
Guangzhou, Guangdong, 510515, China
Location status: Recruiting
Min Liang, MD
CONTACT
Yaya Yang
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention
Time frame: 1 year
The sarcopenia is defined as: Patients with low strength: handgrip <28kg for male or <18kg for female; Or low muscle mass: appendicular skeletal muscle mass/height2 <7kg/m2 for male or <5.7kg/m2 for female; Or low performance: 6-metre walk: <1.0 m/s or 5-time chair stand test: ≥12 s
Time frame: 1 year
The progression of chronic kidney disease is defined as: Patients had a 50% or greater decrease in baseline eGFR <60 ml /min/1.73m2; Or end-stage renal disease (eGFR <15 ml /min/1.73m2, or initiation of renal replacement therapy)
Time frame: 1 year
All-cause mortality is defined as the death due to any reasons.
Time frame: 1 year
CVD mortality included cerebrovascular accidents, heart failure, myocardial infarction, cardiac arrest, death caused by malignant arrhythmias, and sudden death.
Time frame: 1 year
Cardiovascular events included stroke, myocardial infarction, angina, congestive heart failure and other cardiovascular events.
Time frame: 1 year
Hospitalization for any reason
Time frame: 1 year
Rate of participants with fall.
Time frame: 1 year
Rate of participants with bone fracture.
Time frame: 1 year
The quality of life is assessd by 12-item Short-Form Health Survey Questionnaire (SF-12) Survey Questionnaire (SF-12)
Time frame: 1 year
Frailty is assessed by The FRAIL Scale. The FRAIL Scale consists of five items: fatigue, resistance, ambulation, illness, and loss of weight. The scores range from 0 to 5,with 3 to 5 as frail, 1 to 2 as pre-frail, and 0 as normal.
Contact information is provided by the study sponsor or research team.
Min Liang, MD
CONTACT
Yaya Yang
CONTACT
Nanfang Hospital, Southern Medical University
Other
Risk Factors of Chronic Kidney Disease-related Sarcopenia and Its Relationship With Poor Prognosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06109662
Atrophy, Chronic Disease
Derby, United Kingdom
View Trial DetailsNCT03179657
Atrophy, Body Weight
View Trial DetailsNCT03798418
Atrophy, Bone Diseases
Changhua, Taiwan
View Trial DetailsNCT03788252
Atrophy, Chronic Disease
Gumi, Gyeongsangbuk-do, South Korea
View Trial Details